Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Total Non-current Assets
All assets not expected to be converted to cash within one year.
Maze Therapeutics, Inc.NASDAQ: MAZE
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets rises 20.5% from a year ago
Total non-current assets stood at $39.93M at the end of Q1 FY2026, up 20.5% from a year earlier and down 15.8% from the prior quarter. Over 3 fiscal years it compounded at +2.7% a year.
Context
- Total non-current assets amounted to 9.5% of total assets at the end of Q1 FY2026, down 0.4 pp from a year earlier.
- Total non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps rising in the next quarterly balance sheet after a +20.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 47.41M USD
- Year-over-year change
- +22.0%
- 3-year CAGR
- +2.7%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 47.41M | +22.0% |
| FY2024 | 2024-12-31 | 38.87M | +3.9% |
| FY2023 | 2023-12-31 | 37.39M | -14.6% |
| FY2022 | 2022-12-31 | 43.81M | — |
Total Non-current Assets vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +20.5% is the 4th highest of 8, against a peer median of -2.5%.
- Total non-current assets amounts to 9.5% of total assets for MAZE, versus a peer median of 18.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $633.12M USD | +75.2% | -14.8% | 19.5% | |
| Sep 2026 | $214.78M USD | +28.2% | -3.6% | 25.3% | |
| Mar 2026 | $122.64M USD | +25.8% | +48.5% | 24.3% | |
SEPNSepterna, Inc. | Sep 2026 | $112.06M USD | -2.5% | +252.5% | 18.1% |
| Mar 2026 | $39.93M USD | +20.5% | +2.7% | 9.5% | |
BIOABioAge Labs, Inc. | Mar 2026 | $5.79M USD | -69.6% | +172.8% | 1.5% |
| Dec 2025 | €5.04M EUR | -32.4% | -19.4% | 2.0% | |
| Mar 2026 | $717K USD | -49.1% | +9.8% | 1.4% | |
| Peer median (excluding MAZE) | — | -2.5% | +9.8% | 18.1% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.